Canadian pharma wins licence dispute as another continues

A Canadian pharmaceuticals company has defeated an ICC claim brought against it by an Irish counterpart over the marketing of a drug used to treat a chronic intestinal condition, as a separate US$365 million claim it faces from an Italian company continues.

Unlock unlimited access to all Global Arbitration Review content